Nivolumab (Opdivo) demonstrates survival benefit in squamous and non-squamous non-small cell lung cancer (NSCLC)

Last Updated on

October 11, 2015 – In recent months, Nivolumab (Opdivo), a human IgG4 anti-PD-1 monoclonal antibody which targets the PD-1 receptor, had been approved first for the treatment of unresectable  or advanced (metastatic) melanoma and secondly for the treatment of advanced (metastatic) squamous non-small cell lung cancer (NSCLC). This week, the American  Food and Drug Administration approved Nivolumab (Opdivo) to also treat patients with advanced (metastatic) squamous non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.

Lung cancer is one of the leading cause of cancer death in the US and worldwide. The most common type of lung cancer, non-small cell lung cancer (NSCLC), is further divided into two main types named for the kinds of cells found in the cancer, namely squamous cells and non-squamous cells (which includes adenocarcinoma). Nivolumab (Opdivo) works by targeting the cellular pathway known as PD-1/PD-L1 (proteins found on the body’s immune cells and some cancer cells). By blocking this pathway, Nivolumab (Opdivo) may help the body’s immune system fight the cancer cells. The approval of Nivolumab (Opdivo) earlier this year was for the treatment of patients with advanced squamous NSCLC whose disease progressed during or after platinum-based chemotherapy. The current approval now expands the use of Opdivo to also treat patients with non-squamous NSCLC.

The effectiveness of Nivolumab (Opdivo) for this indication was demonstrated in an international, open-label, randomized study of 582 participants with advanced non-squamous NSCLC whose disease progressed during or after treatment with platinum-based chemotherapy and appropriate biologic therapy. Participants were treated with Nivolumab (Opdivo) or docetaxel. The primary endpoint was overall survival, and the secondary endpoint was objective response rate (the percentage of Non-Squamous NSCLCpatients who experienced complete or partial shrinkage of their tumors). Those treated with Nivolumab (Opdivo) lived an average of 12.2 months compared to 9.4 months in those treated with docetaxel. Additionally, 19 percent of those treated with Nivolumab (Opdivo) experienced a complete or partial shrinkage of their tumors, an effect that lasted an average of 17 months, compared to 12 percent among those taking docetaxel, which lasted an average of six months.

According to Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, there remains still a lot to be learned about the PD-1/PD-L1 pathway and its effects in lung cancer, as well as other tumor types. Thus, while patients who received Nivolumab (Opdivo) lived longer than those who received docetaxel across the study, an evaluation of samples from a subgroup of patients’ tumors suggests that the level of PD-L1 expression in NSCLC tumors may help identify patients who are more likely to live longer due to treatment with Nivolumab (Opdivo). Therefore the FDA also approved the PD-L1 IHC 28-8 pharmDx test to detect PD-L1 protein expression levels and help physicians determine which patients may benefit most from treatment with Nivolumab (Opdivo).

Another drug called Pembrolizumab (Keytruda) also targets the PD-1/PD-L1 pathway. It was approved just last week for treating NSCLC specifically for patients whose tumors expressed PD-L1. Thasso Post had a recent report on Pembrolizumab (Keytruda).

As one might expect from immune checkpoint modulating drugs, Nivolumab (Opdivo) comes with a rather serious and complicated clinical safety profile, which in some patients simply may lead to therapy terminating events with sometimes fatal outcome. In an earlier article in Thasso Post, inclusive the comment section to this article, these clinical safety concerns with respect to Opdivo have substantiated.

Follow below a commentary by Corey Langer, MD, on the immune checkpoint therapy approach involving  Nivolumab (Opdivo):

Tags: , , , , , , , , , , ,
About the Author
thassodotcom Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Leave a Reply

Optional: Social Subscribe/Login




avatar
  Subscribe  
Notify of
mywebsite
Guest

Hey very interesting blog!

tinyurl.com
Guest

whoah this weblog is excellent i love reading your
posts. Stay up the good work! You already know, a lot
of persons are searching around for this information, you could help them greatly.

Coconut Oil Benefits
Guest

What’s up mates, pleasant post and good urging commented at this place, I am
really enjoying by these.

Coconut Oil Benefits
Guest

Thanks for sharing your thoughts about nivolumab (opdivo).
Regards

minecraft
Guest

You really make it seem so easy with your presentation but I find this
topic to be actually something that I think I would never
understand. It seems too complicated and extremely broad for me.
I am looking forward for your next post, I’ll try to get the hang
of it!

minecraft
Guest

Genuinely when someone doesn’t understand then its up to
other visitors that they will help, so here it occurs.

Menlo-50
Guest

On November 23, 2015, the U.S. Food and Drug Administration approved Nivolumab (Opdivo) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy. “Opdivo provides an important therapy option for patients with renal cell carcinoma,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “It is one of few therapies that have demonstrated the ability to extend patients’ survival in treating this disease.” In fact, Torisel (temsirolimus), approved in 2007, is the only other… Read more »

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • New study shows how cancer survivors develop opioid addictions November 22, 2019
    Opioids play an important role in how cancer patients manage pain, but the ongoing opioid epidemic has raised concerns about their potential for abuse. A new study in the Journal of the National Cancer Institute reveals that several factors are associated with a risk for persistent opioid use, including younger age, white race, unemployment at […]
  • Lack of sleep may explain why poor people get more heart disease November 22, 2019
    Insufficient sleep is one reason why disadvantaged groups have more heart disease. That's the finding of a study published today in Cardiovascular Research, a journal of the European Society of Cardiology (ESC).
  • Women raised in poor neighborhoods face an increased risk of intimate partner violence November 21, 2019
    Women who spend longer periods of their early lives in less affluent neighbourhoods are at greater risk of experiencing violence during their early adulthoods at the hands of their intimate partners, finds a new study published in Epidemiology.
  • A review of single molecule-based electronic devices November 21, 2019
    In a paper to be published in the forthcoming issue in NANO, a group of researchers from the Shenyang Jianzhu University in China provide an overview of single molecule electronic devices, including molecular electronic devices and electrode types. Future challenges are described in the hopes of attracting more experts from different fields to participate in […]
  • Wolfe Creek Crater younger than previously thought November 21, 2019
    Wolfe Creek Crater, one of the world's largest meteorite craters, is much younger than previously thought.
Top